Efficacy Evaluation of Wasabi Leaf Extract on Skin
Study Details
Study Description
Brief Summary
To assess the efficacy of Wasabi Leaf Extract on skin
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Placebo drink
|
Dietary Supplement: Placebo drink
consume 1 bottle per day
|
| Experimental: Wasabi Leaf Extract Drink
|
Dietary Supplement: Wasabi Leaf Extract Drink
consume 1 bottle per day
Other Names:
|
Outcome Measures
Primary Outcome Measures
- The change of skin melanin index [Change from Baseline skin melanin index at 8 weeks]
Mexameter® MX18 was utilized to measure skin melanin index. Units: arbitrary Mexameter® units (0-999)
- The change of skin erythema index [Change from Baseline skin erythema index at 8 weeks]
Mexameter® MX18 was utilized to measure skin erythema index. Units: arbitrary Mexameter® units (0-999)
- The change of skin sebum content [Change from Baseline skin sebum content at 8 weeks]
Sebumeter® SM815 was utilized to measure skin sebum content. Units: Sebumeter® units from 0-350
- The change of transepidermal water loss [Change from Baseline TEWL at 8 weeks]
Tewameter® TM300 was utilized to measure transepidermal water loss (TEWL). Units: TEWL-values lower than 70 g/hm²
- The change of L* (lightness) values [Change from Baseline L* value at 8 weeks]
Spectrophotometer SCM-108 was utilized to measure skin L* value. Units: arbitrary units
- The change of a* (redness) values [Change from Baseline a* value at 8 weeks]
Spectrophotometer SCM-108 was utilized to measure skin a* value. Units: arbitrary units
- The change of visible spots [Change from Baseline visible spots at 8 weeks]
VISIA Complexion Analysis System was utilized to measure skin spots. Units: arbitrary units
- The change of skin red area [Change from Baseline skin red area at 8 weeks]
VISIA Complexion Analysis System was utilized to measure skin red area. Units: arbitrary units
- The change of total antioxidant capacity of blood [Change from Baseline total antioxidant capacity at 8 weeks]
Venous blood was sampled to measure total antioxidant capacity
- The change of Interleukin-6 of blood [Change from Baseline IL-6 at 8 weeks]
Venous blood was sampled to measure IL-6
- The change of Interleukin-8 of blood [Change from Baseline IL-8 at 8 weeks]
Venous blood was sampled to measure IL-8
- The change of Insulin-Like Growth Factor-1 of blood [Change from Baseline IGF-1 at 8 weeks]
Venous blood was sampled to measure IGF-1
Secondary Outcome Measures
- The change of skin hydration [Change from Baseline skin hydration at 8 weeks]
Corneometer® CM825 was utilized to measure skin hydration. Units: arbitrary
- The change of UV spots [Change from Baseline UV spots at 8 weeks]
VISIA Complexion Analysis System was utilized to measure UV spots. Units: arbitrary units
- The change of brown spots [Change from Baseline brown spots at 8 weeks]
VISIA Complexion Analysis System was utilized to measure brown spots. Units: arbitrary units
- The change of Advanced glycation end products of blood [Change from Baseline AGEs at 8 weeks]
Venous blood was sampled to measure AGEs
- The change of liver function biomarkers (AST, ALT) of blood [Change from Baseline liver function biomarkers at 8 weeks]
Venous blood was sampled to measure liver function biomarkers
- The change of renal function biomarkers (creatinine, BUN) of blood [Change from Baseline renal function biomarkers at 8 weeks]
Venous blood was sampled to measure renal function biomarkers
- The change of fasting blood glugose level [Change from Baseline fasting blood glugose level at 8 weeks]
Venous blood was sampled to measure fasting blood glugose level
- The change of blood lipid profile [Change from Baseline blood lipid profile at 8 weeks]
Venous blood was sampled to measure blood lipid profile (total cholesterol, HDL-C, LDL-C, triglyceride)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
20 to 65-year-old males or females
-
People with dull skin, pigmentation spots or acne-prone, acne scars
-
Acne severity assessment- Investigator's Global Assessment Scale (IGA) ≥ 2
Exclusion Criteria:
-
Received medical cosmetic treatment (including cosmetic skin care, laser, fruit acid peeling, injection or plastic surgery, etc.) currently or within one month before the trial
-
Outdoor workers (exposed to the sun more than 5 hours a day)
-
People who are breastfeeding, pregnant or planning to become pregnant during the test (self-report)
-
People with heart, liver, kidney, endocrine and other major organic diseases (self-reported)
-
People who have undergone major surgery (according to medical history)
-
People who take drugs for a long time
-
People with mental illness
-
Students who are currently taking courses taught by the principal investigator of this trial
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | China Medical University | Taichung | Taiwan |
Sponsors and Collaborators
- TCI Co., Ltd.
Investigators
- Principal Investigator: Hsiu-Mei Chiang, Prof., China Medical University, China
- Study Director: Po-Yuan Wu, Dr., China Medical University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CMUH111-REC3-028